LAVAL, Quebec, Feb. 13, 2012 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (TSX-V:APO) announces that further to its news release dated February 7, 2012, it has closed a private placement pursuant to which Dr. Harlan Waksal, Acasti’s Executive Vice-President, Business & Scientific Affairs, and Neptune Technologies & Bioressources Inc. (“Neptune”), Acasti’s parent company, have subscribed to Acasti’s capital stocks for total net proceeds of approximately $2,000,000 CDN (the “Offering”).
